Drug Profile
CA 102 N
Alternative Names: CA102N; HA-Nimesulide; Hyaluronic acid nimesulide-NH2 bioconjugate; Nim-HA ConjugateLatest Information Update: 02 May 2024
Price :
$50
*
At a glance
- Originator Holy Stone Healthcare
- Class Adjuvants; Antineoplastics; Drug conjugates; Glycosaminoglycans; Nonsteroidal anti-inflammatories; Sulfonamides
- Mechanism of Action Apoptosis stimulants; Calcium channel antagonists; CD44 antigen inhibitors; Cyclo-oxygenase 2 inhibitors; Hyaluronic acid modulators; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Colorectal cancer; Solid tumours
- Preclinical Pancreatic cancer
Most Recent Events
- 19 Apr 2024 Preclinical trials in Pancreatic cancer in Taiwan (unspecified route), prior to April 2024
- 19 Apr 2024 Holy Stone Healthcare intends to seek orphan drug designation from the US FDA for CA 102 N in USA
- 19 Apr 2024 Pharmacodynamics data from a preclinical trial in Pancreatic cancer released by Holy Stone Healthcare